Viruses are known to be highly susceptible to mutations, often resulting in the emergence of variant strains. While some will disappear, others will persist and challenge our global healthcare system, just as we saw with the COVID-19 pandemic.
The pandemic is the most recent example of why rapid development of new detection strategies is more crucial than ever, especially when new variants demonstrate improved transmissibility or virulence. Co-presented by OCMS Bio and Nicoya Lifesciences, this webinar will present current strategies being applied in antibody discovery to accelerate the development of diagnostic tools for emerging viral variants.
Join us in a conversation with Scott Dessain (OCMS) and Marko Jovic (Nicoya), who will discuss the application of novel mAb screening technology and surface plasmon resonance (SPR) for rapid discovery and characterization of variant-specific antibodies, and will delve into the future of immunodiagnostics.
Founder & CSO, OCMS Bio
Scott Dessain, MD, PhD and Founder/CSO of OCMS Bio is a medical oncologist and immunologist who developed the OCMS® technology in his laboratory at the Lankenau Institute for Medical Research. He is also the co-founder of Immunome, Inc.
Training & Development Manager, Nicoya
